Trials / Unknown
UnknownNCT06135194
Efficacy of T-Dxd in the Treatment of HER2-positive BCBM After Prior Pyrotinib
Efficacy and Safety of T-Dxd in the Treatment of HER2-positive Breast Cancer With Brain Metastases After Prior Pyrotinib Treatment
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 30 (estimated)
- Sponsor
- Beijing 302 Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of T-DXd in the treatment of HER2-positive breast cancer with brain metastases after treatment with pyrotinib
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | T-DXd | Efficacy and safety of T-DXd in the treatment of HER2-positive breast cancer with brain metastases after treatment with pyrotinib |
Timeline
- Start date
- 2021-04-01
- Primary completion
- 2023-12-30
- Completion
- 2024-06-30
- First posted
- 2023-11-18
- Last updated
- 2023-11-18
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06135194. Inclusion in this directory is not an endorsement.